TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01907386

Intervention type: OTHER
Group type: OTHER
Intervention: QSE-LSME - SSWI Ultrasound
Description: Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
Study: NCT02312973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat(BAY85-3934)
Description: Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat(BAY85-3934)
Description: Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
Study: NCT03291093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flutemetamol PET/MRI
Description: All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flutemetamol PET/MRI
Description: All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flutemetamol PET/MRI
Description: All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
Study: NCT02889029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new 3D device
Description: dedicated tailored stents wrought by 3D computer-assisted conception
Study: NCT04267224

Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.

Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
Study: NCT00363545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized formulation of HRV vaccine
Description: Lyophilized formulation of HRV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid formulation of HRV vaccine
Description: Liquid formulation of HRV vaccine
Study: NCT01158001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure therapy
Description: Twelve sessions (90 minutes each) of prolonged exposure therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Description: Twelve sessions (90 minutes each) of prolonged exposure therapy
Study: NCT01588470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: 45 mg per day for 6 months
Study: NCT04583059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
Study: NCT03417713

Intervention type: DEVICE
Intervention: Fluoroscopic imaging with the OEC Elite Device
Description: Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
Study: NCT04580641

Intervention type: OTHER
Intervention: Questionnaire
Description: A self-administered questionnaire will be completed by each study subject
Study: NCT04501692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VivaSight
Description: see above

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscopy
Description: see above
Study: NCT02916290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Study: NCT03900325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimacimab
Description: 2.5 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study: NCT02941172

Intervention type: OTHER
Group type: OTHER
Intervention: Cold exposure
Description: Controlled cold exposure is performed before and during PET scan

Intervention type: OTHER
Group type: OTHER
Intervention: Cold exposure
Description: Controlled cold exposure is performed before and during PET scan

Intervention type: OTHER
Group type: OTHER
Intervention: [18F]FMPEP-d2
Description: PET radiotracer used in imaging

Intervention type: OTHER
Group type: OTHER
Intervention: [18F]FMPEP-d2
Description: PET radiotracer used in imaging

Intervention type: OTHER
Group type: OTHER
Intervention: [18F]FDG
Description: PET radiotracer used in imaging
Study: NCT04017195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
Study: NCT02916290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Study: NCT03463369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64300535
Description: Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 1 mL (0.9 percent \[%\] sodium chloride \[NaCl\]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogs (NA)
Description: Participants will receive NA as a standard of care treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogs (NA)
Description: Participants will receive NA as a standard of care treatment.
Study: NCT01029470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris
Description: Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
Study: NCT03375684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
Study: NCT02312973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat(BAY85-3934)
Description: One single oral dose of 75 mg molidustat in healthy subjects
Study: NCT00136812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stage-tailored intervention
Description: This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
Study: NCT02999620

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-cyclodextrin
Description: Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo tablet to active (Alpha-cyclodextrin)
Study: NCT02738671

Intervention type: BEHAVIORAL
Intervention: Cognitive assessment

Intervention type: BEHAVIORAL
Intervention: Cognitive assessment
Study: NCT03474055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid Rotavirus Vaccine
Description: Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid Rotavirus Vaccine
Description: Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid Rotavirus Vaccine
Description: Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Rotavirus Vaccine
Description: Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
Study: NCT03885778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir dipivoxil
Description: 150mg Besifovir dipivoxil, single dose, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir dipivoxil
Description: 150mg Besifovir dipivoxil, single dose, oral
Study: NCT02502864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care: Docetaxel
Description: Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m\^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care: Cyclophosphamide
Description: Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Function Assessment of Cancer Therapy (FACT) Surveys
Description: Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
Study: NCT03670355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) IVR
Description: Contains 1.4 g TFV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVR
Description: Contains placebo
Study: NCT04017195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
Study: NCT03141944

Intervention type: OTHER
Intervention: Starkstein scale of Apathy
Description: The degree of apathy will be evaluated with the Starkstein scale of Apathy

Intervention type: OTHER
Intervention: Starkstein scale of Apathy
Description: The degree of apathy will be evaluated with the Starkstein scale of Apathy
Study: NCT01661790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 30mg,intrapleural administration,each 2 week
Study: NCT04017195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
Study: NCT01661790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 30mg,intrapleural administration,each 2 week
Study: NCT03152942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
Study: NCT03152942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
Study: NCT01247311

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement
Description: Placebo given orally 3xweek for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 5000 IU vitamin D given orally 3xweek for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 0.5ug 1,25 vitamin D given orally 3xweek for six months
Study: NCT04492566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery
Description: Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy.
Study: NCT04812561

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bronch™
Description: 2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
Study: NCT04017195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
Study: NCT01671527

Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.

Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.

Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
Study: NCT03693560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg Oral Tablet
Description: Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg Oral Tablet
Description: Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg Oral Tablet
Description: Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride upto 4 mg Oral Tablet
Description: Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
Study: NCT00254267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 125mg, oral, once a day
Study: NCT03409887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraorifice barrier of GIC
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Base of GIC
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite restoration
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
Study: NCT00936728

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic nutritional supplementation
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: white wine
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01048346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support Model
Description: Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
Study: NCT01202591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Tablet oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Tablet oral twice daily
Study: NCT02342418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tedizolid phosphate
Description: Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tedizolid phosphate
Description: Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
Study: NCT01909011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CES
Description: The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CES
Description: The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
Study: NCT01806662

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Injection of monoclonal antibody against the p40 subunit of IL-12/23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Injection of monoclonal antibody against the p40 subunit of IL-12/23

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of placebo
Study: NCT02739178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSF Intervention
Description: Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.